Eli Lilly Files 8-K: Director Changes and Compensation Details
Ticker: LLY · Form: 8-K · Filed: Sep 9, 2024 · CIK: 59478
| Field | Detail |
|---|---|
| Company | Eli Lilly & Co (LLY) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, board-of-directors
Related Tickers: LLY
TL;DR
Lilly's board is shuffling, with Smith out and Ricks/Finucane in. Compensation details also filed.
AI Summary
Eli Lilly and Company (LLY) filed an 8-K on September 9, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, including David A. Ricks and Anne M. Finucane. The filing also details compensatory arrangements for certain officers and includes financial statements and exhibits related to the company's operations.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance and executive compensation disclosures, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Eli Lilly and Company (company) — Filer
- Michael J. Smith (person) — Departing Director
- David A. Ricks (person) — Newly Elected Director
- Anne M. Finucane (person) — Newly Elected Director
- 0000059478-24-000213 (filing_id) — Accession Number
FAQ
Who has departed from Eli Lilly's board of directors?
Michael J. Smith has departed from Eli Lilly's board of directors.
Who has been elected to Eli Lilly's board of directors?
David A. Ricks and Anne M. Finucane have been elected to Eli Lilly's board of directors.
What other information is included in this 8-K filing?
The filing includes details on compensatory arrangements for certain officers, as well as financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on September 9, 2024.
What is the standard industrial classification for Eli Lilly & Co?
The standard industrial classification for Eli Lilly & Co is Pharmaceutical Preparations [2834].
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 9.7 · Accepted 2024-09-09 07:03:46
Key Financial Figures
- $1,000,000 — ll receive an annualized base salary of $1,000,000 and will be eligible for an annualized
Filing Documents
- lly-20240905.htm (8-K) — 51KB
- ecannouncement_pressreleas.htm (EX-99.1) — 11KB
- image_0a.jpg (GRAPHIC) — 13KB
- image_1a.jpg (GRAPHIC) — 12KB
- 0000059478-24-000213.txt ( ) — 318KB
- lly-20240905.xsd (EX-101.SCH) — 5KB
- lly-20240905_def.xml (EX-101.DEF) — 19KB
- lly-20240905_lab.xml (EX-101.LAB) — 37KB
- lly-20240905_pre.xml (EX-101.PRE) — 20KB
- lly-20240905_htm.xml (XML) — 10KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated September 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Anat Hakim Name: Anat Hakim Title: Executive Vice President, General Counsel and Secretary Date: September 9, 2024